Reactive Conjugates for Regioselective Antibody Payload Attachment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing antibody-drug conjugates (ADCs) often result in heterogeneous mixtures due to varying payload antibody ratios and conjugation sites, leading to batch variability and unpredictable safety and efficacy, and require multiple steps or modifications that can affect the antibody's therapeutic efficacy and immune response.
Innovation Solution
A compound represented by the formula P—Y—S—V, where P is a payload, Y is a reactive moiety that reacts with amino acid side chains, and V is a vector interacting with the Fc region of an antibody, allowing for regioselective attachment of the payload to antibodies or antibody fragments in a single step without modifying the antibody, enabling the production of modified antibodies for diagnostic, monitoring, or therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional ADC preparation methods are used, then payloads can be attached to antibodies, but heterogeneous mixtures with varying payload antibody ratios and conjugation sites are produced, leading to batch variability and unpredictable safety and efficacy
Solution Approach 1:
The patent introduces a heterobifunctional crosslinking agent as an intermediary that mediates the conjugation between payload and antibody. The crosslinking agent has a first reactive group that specifically reacts with amino acid residues on the antibody and a second reactive group that reacts with the payload, enabling controlled and homogeneous conjugation with consistent payload antibody ratios
Solution Approach 2:
The patent controls the conjugation process by adjusting parameters including the molar ratio of crosslinking agent to antibody, reaction pH, temperature, and incubation time. These parameter optimizations ensure homogeneous conjugation products with consistent payload antibody ratios and reduced batch variability
2Manufacturing precision
If regiospecific and site-specific conjugation methods are used, then homogeneous mixtures with predictable payload conjugation sites can be produced, but antibody modification or engineering is required which may negatively affect therapeutic efficacy and safety
Solution Approach 1:
The patent employs a self-service approach where the crosslinking agent autonomously directs its own positioning through its dual reactivity: the first reactive group automatically targets and binds to accessible amino acid residues on the antibody surface, while the second reactive group then reacts with the payload. This self-directed mechanism achieves site-specific conjugation without requiring antibody engineering
Solution Approach 2:
The crosslinking agent acts as a disposable intermediary that facilitates the conjugation process and is then removed or remains as a stable, non-interfering part of the final conjugate. This approach avoids the need for complex, reusable antibody engineering processes while achieving the desired site-specific conjugation
3Manufacturing precision
If multi-step approaches are used, then regiosspecific conjugation can be achieved, but the process becomes costly and laborious, making it less attractive for applications requiring quick and simple antibody modification
Solution Approach 1:
The patent merges multiple conjugation steps into a single reaction step by using a pre-designed heterobifunctional crosslinking agent that contains both the antibody-reactive group and the payload-reactive group. This allows simultaneous achievement of site-specific conjugation and payload attachment in one pot, dramatically reducing process time and complexity
Solution Approach 2:
The crosslinking agent is pre-prepared with both reactive groups in the correct orientation and configuration before the conjugation reaction. This preliminary preparation eliminates the need for sequential steps during the actual conjugation process, enabling rapid and efficient antibody modification while maintaining high specificity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of ADCs with predictable payload conjugation sites and ratios, simplifying manufacturing and reducing batch variability, while maintaining the antibody's therapeutic efficacy and safety by achieving site-specific conjugation in a single step.
Implementation Method 1
Y is a reactive moiety capable of reacting with the side chain of an amino acid
Data Source
AI summary
The present invention relates to compounds (reactive conjugates) for the chemical modification of therapeutic antibodies or proteins. The compounds enable the regioselective attachment of a payload to an antibody or antibody fragment in one single step, thereby producing a modified antibody or modified antibody fragment, which can be used for diagnosing, monitoring, imaging or treating disease.